Mediator, pg/ml | LLD | HIV unexposed (HU) | HIV exposed uninfected (HEU) | pb | ||
---|---|---|---|---|---|---|
na | Median (IQR) | na | Median (IQR) | |||
Pro-inflammatory | ||||||
IL-6 | 0.2 | 17 | 1 (1–6) | 29 | 24 (2–155) | 0.001 |
IL-23 | 8.0 | 16 | 8 (8–16) | 30 | 8 (8–8) | 0.001 |
IL-1β | 0.5 | 18 | 4 (1–39) | 28 | 7 (0.5–102) | 0.800 |
TNF-α | 0.4 | 19 | 18 (15–26) | 30 | 15 (9–38) | 0.300 |
Chemotactic | ||||||
IL-8/CXCL8 | 0.3 | 19 | 13 (7–26) | 29 | 748 (93–1882) | < 0.001 |
CXCL11 | 1.5 | 19 | 372 (279–428) | 30 | 154 (65–254) | < 0.0001 |
CCL3 | 0.3 | 19 | 34 (17–70) | 30 | 176 (29–1901) | 0.030 |
CCL4 | 1.0 | 19 | 67 (61–121) | 22 | 71 (290–152) | 0.600 |
CCL20 | 0.6 | 19 | 40 (27–57) | 26 | 47 (32–133) | 0.100 |
CX3CL1 | 18.0 | 17 | 18 (18–28) | 30 | 18 (18–18) | 0.006 |
Immunoregulatory | ||||||
IL-21 | 0.2 | 15 | 0.2 (0.2–0.2) | 30 | 0.7 (0.3–2.2) | 0.001 |
IL-7 | 0.4 | 19 | 6 (2–13) | 30 | 2 (0.4–4) | 0.003 |
Th2 | ||||||
IL-5 | 0.5 | 17 | 0.6 (0.5–0.9) | 30 | 0.5 (0.5–0.5) | < 0.0001 |
IL-10 | 1.5 | 16 | 1.5 (1.5–7) | 29 | 3 (1.5–6) | 0.100 |
GM-CSF | 1.2 | 19 | 7 (3–13) | 30 | 5 (1.2–17) | 0.700 |